Sinovac Biotech (北京科兴生物制品有限公司) received an order for 87 million RMB ($12.8 million) of its inactivated hepatitis A vaccine, Healive® from China's Ministry of Public Health (MOH). In 2008, Sinovac recorded revenues of $46.5 million, 88% of which came from Healive. To improve public health, the MOH is undertaking a hepatitis A vaccination campaign that will cover young children from 18 months to 12 years old in 32 cities or counties in nine provinces. More details...

Stock Symbol: (NYSE Amex: SVA)